AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Precision Radiation Oncology Article
Article Link
Cite
EndNote(RIS) BibTeX
Collect
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Stereotactic body radiation therapy for clinically diagnosed early-stage non-small cell lung cancer: Importance of accurate CT interpretation by experts

Daisuke Nakamura1,2, Koichi Honda1, Takuya Yamazaki3, Hideyuki Hayashi4, Shin Tsutsui3, Aya Fukushima3, Sumihisa Honda5, Masataka Uetani3, Kazuto Ashizawa1( )
Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Department of Radiology, NHO Nagasaki Medical Center, Omura, Japan
Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Department of Radiology, JCHO Isahaya General Hospital, Isahaya, Japan
Department of Public Health & Nursing, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Show Author Information

Abstract

Introduction

This study evaluated the clinical outcomes of stereotactic body radiotherapy (SBRT) for both pathologically diagnosed (PD) and clinically diagnosed (CD) early-stage non-small cell lung cancer (NSCLC) and explored the significance of accurate expert computed tomography (CT) interpretation.

 Methods

We retrospectively analyzed 95 patients with early-stage NSCLC who received SBRT at our institution. Patients were classified into CD and PD groups. Two chest radiologists retrospectively interpreted the pre-SBRT CT images to determine the tumor subtype and probability of malignancy (PM). Clinical findings, CT features, and treatment outcomes were compared between the two groups. The survival rate of the CD group was analyzed separately according to the PM grade.

 Results

Median overall survival for the CD and PD groups was 6.0 and 5.4 years (P = 0.57), respectively. Median cause-specific survival was 10.2 years in the CD group and not reached in the PD group (P = 0.76). In the CD group, lung cancer mortality was lower in the low PM group (25% [1 of 4]) than in the high PM group (47.4% [9 of 19]).

 Conclusion

It may be desirable to evaluate the PM of the nodule using expert CT interpretation to decide whether SBRT is indicated in CD early-stage NSCLC.

Keywords

lung neopasmsoncologic imagingradiation oncology imaging

References

1

Sebastian NT, Merritt RE, Abdel-Rasoul M, et al. Recurrence After Stereotactic Body Radiation Therapy Versus Lobectomy for Non-Small Cell Lung Cancer. Ann Thorac Surg. 2020;110(3):998-1005.
Crossref Google Scholar
2

Bei Y, Murakami N, Nakayama Y, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment. J Radiat Res. 2020;61(4):586-593.
Crossref Google Scholar
3

Schneider BJ, Daly ME, Kennedy EB, et al. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2018;36(7):710-719.
Crossref Google Scholar
4

Nakajo M, Jinguji M, Aoki M, Tani A, Sato M, Yoshiura T. The clinical value of texture analysis of dual-time-point (18)F-FDG-PET/CT imaging to differentiate between (18)F-FDG-avid benign and malignant pulmonary lesions. Eur Radiol. 2020;30(3):1759-1769.
Crossref Google Scholar
5

Berman AT, Jabbour SK, Vachani A, et al. Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. Transl Lung Cancer Res. 2019;8(1):5-14.
Crossref Google Scholar
6

Shaikh T, Churilla TM, Murphy CT, et al. Absence of Pathological Proof of Cancer Associated with Improved Outcomes in Early-Stage Lung Cancer. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer. 2016;11(7):1112-1120.
Crossref Google Scholar
7

Dautruche A, Filion E, Mathieu D, et al. To Biopsy or Not to Biopsy?: A Matched Cohort Analysis of Early-Stage Lung Cancer Treated with Stereotactic Radiation with or Without Histologic Confirmation. Int J Radiat Oncol Biol Phys. 2020;107(1):88-97.
Crossref Google Scholar
8

MA IJ, Shoni M, Siegert C, et al. Survival After Stereotactic Body Radiation Therapy for Clinically Diagnosed or Biopsy-Proven Early-Stage NSCLC: A Systematic Review and Meta-Analysis. J Thorac Oncol: official publication of the International Association for the Study of Lung Cancer. 2019;14(4):583-595.
Crossref Google Scholar
9

Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase Ⅱ trial of medically inoperable stage Ⅰ non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27(20):3290-3296.
Crossref Google Scholar
10

Haidar YM, Rahn DA, 3rd, Nath S, et al. Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation. Ther Adv Respir Dis. 2014;8(1):3-12.
Crossref Google Scholar
11

Lagerwaard FJ, Verstegen NE, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage Ⅰ non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348-353.
Crossref Google Scholar
12

Rosen LR, Fischer-Valuck BW, Katz SR, et al. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center. Tumori. 2014;100(1):42-48.
Crossref Google Scholar
13

Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
Crossref Google Scholar
14

Nakata M, Saeki H, Takata I, et al. Focal ground-glass opacity detected by low-dose helical CT. Chest. 2002;121(5):1464-1467.
Crossref Google Scholar
15

Kinoshita F, Toyokawa G, Matsubara T, et al. Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas. Anticancer Res. 2019;39(5):2665-2670.
Crossref Google Scholar
16

Iwano S, Umakoshi H, Kamiya S, et al. Postoperative recurrence of clinical early-stage non-small cell lung cancers: a comparison between solid and subsolid nodules. Cancer Imaging. 2019;19(1):33.
Crossref Google Scholar
17

Miyazaki T, Yamazaki T, Nakamura D, et al. Surgery or stereotactic body radiotherapy for elderly stage Ⅰ lung cancer? A propensity score matching analysis. Surg Today. 2017;47(12):1476-1483.
Crossref Google Scholar
18

Chang JY, Mehran RJ, Feng L, et al. Stereotactic ablative radiotherapy for operable stage Ⅰ non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021;22(10):1448-1457.
Crossref Google Scholar
19

Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ. 2016;354:i3570.
Crossref Google Scholar
20

Kawai H, Tada A, Kawahara M, et al. Smoking history before surgery and prognosis in patients with stage ⅠA non-small-cell lung cancer–a multicenter study. Lung Cancer. 2005;49(1):63-70.
Crossref Google Scholar
21

Roach MC, Rehman S, DeWees TA, Abraham CD, Bradley JD, Robinson CG. It’s never too late: Smoking cessation after stereotactic body radiation therapy for non-small cell lung carcinoma improves overall survival. Pract Radiat Oncol. 2016;6(1):12-18.
Crossref Google Scholar
22

Timmerman RD, Hu C, Michalski JM, et al. Long-term Results of Stereotactic Body Radiation Therapy in Medically Inoperable Stage Ⅰ Non-Small Cell Lung Cancer. JAMA Oncol. 2018;4(9):1287-1288.
Crossref Google Scholar
23

Matsuo Y, Takayama K, Nagata Y, et al. Interinstitutional variations in planning for stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2007;68(2):416-425.
Crossref Google Scholar
Precision Radiation Oncology
Volume 8 Issue 1,
May 2024
Pages 30-36
DOI: 10.1002/pro6.1220
Cite this article:
Nakamura D, Honda K, Yamazaki T, et al. Stereotactic body radiation therapy for clinically diagnosed early-stage non-small cell lung cancer: Importance of accurate CT interpretation by experts. Precision Radiation Oncology, 2024, 8(1): 30-36. https://doi.org/10.1002/pro6.1220

192

Views

0

Crossref

0

Scopus

Altmetrics
Received: 17 February 2023
Revised: 18 December 2023
Accepted: 14 January 2024
Published: 10 March 2024
© 2024 The Authors.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Return